ABSTRACT: Bone loss and osteoporosis are major public health problems in the elderly. With increasing life expectancy in the United States, the number of people that will develop age-related bone loss and osteoporosis is expected to rise to over 61 million by 2020. Osteoblast differentiation is a crucial aspect of bone formation and remodeling, a process severely compromised in osteoporosis. Almost all the FDA-approved treatments for building healthier bones, excluding parathyroid hormone (PTH), do not address the decrease in osteoblast differentiation seen in osteoporosis and rather are designed to target osteoclasts and bone resorption. The purpose of this study is to examine the effects of NFAT inhibition on osteoblast differentiation and to elucidate the mechanism of its action. Here we demonstrate that the inhibition of calcineurin (Cn) by using cyclosporine A (CsA) increases osteoblast differentiation, both in vivo and in vitro. Furthermore, the specific inhibition of NFATc1 by siRNA increased Fra-2 expression in osteoblasts. Taken together, our results point the way to a novel mechanism to aid in the development of anabolic treatment for osteoporosis.
INTRODUCTION
NFAT is regulated by Ca 2+ and the Ca 2+ /calmodulin-dependent serinethreonine phosphatase, calcineurin (Cn). In resting cells, NFAT proteins are phosphorylated and reside in the cytoplasm. Upon activation, they are dephosphorylated by Cn, translocate to the nucleus, and become transcriptionally active. Cyclosporin A (CsA) and FK506, widely used immunosuppressive drugs, are known to elicit their responses by decreasing the expression of interleukins primarily via inhibiting the activation of the Cn/NFAT signaling pathway. It is documented that bone disease, in the form of osteopenia and osteoporosis, is a serious complication of organ transplantation in hmans 1 . Although this phenomenon has been attributed to the use of CsA, the role of the underlying disease, pre-and post-transplantation treatments such as steroids, methotrexate and anticoagulants should not be ruled out as contributors to post-transplantation osteoporosis 2 . The role of NFAT in the growth and development of bone have previously focused on the effects of NFAT activation on osteoclastogenesis. The specific roles of Cn and NFAT in osteoblast differentiation are not well understood and in some instances, reports of their roles are contradictory. Here we examine the direct effects of CsA and NFATc1 on osteoblast differentiation.
METHODS
An in vivo mouse calvarial model was used. Briefly, Balb/c mice, 5 days old, were injected for 10 days subcutaneously over the parietal region of the skull. At the end of the study, tissues were washed with PBS, fixed with 10% formalin, and embedded in methyl methacrylate. The murine clonal osteogenic cell line, MC3T3-E1, established from newborn mouse calvaria, was used for this study. Cells were treated with CsA or transfected with an NFATc1 siRNA. At the end of the study, cells were harvested and RNA, and cytoplasmic and nuclear protein extractions were performed. Real-time polymerase chain reaction (PCR), Western blotting, and gel shifts assays were performed.
RESULTS
The inhibition of Cn/NFAT by CsA, in vivo, produces high-turnover osteopenia characterized by an increase in osteoclasts and osteoblast differentiation. 3 In contrast, CsA leads to decreases in osteoclast differentiation and in bone resorption in cultured isolated osteoclasts and neonatal mouse calvarial and fetal rat long bone. 4, 5 To determine the effects of Cn/NFAT inhibition on osteoblast differentiation in vivo we used a mouse calvarial model. This method was previously used by us and by others to examine the direct effect of drugs on osteoblast differentiation. DMSO or CsA (1 M) dissolved in PBS were injected subcutaneously for 10 days into the calvarial region of mouse pups (5 days old). Mice were then sacrificed, calvariae were harvested and tissue was processed for staining and bone histomorphometry. Treatment with CsA dramatically increased the number of osteoblasts (FIG. 1) and bone mineralization. Histomorphometric analyses of calvariae demonstrate a 31% increase in osteoblast number (N.Ob-BS) and an 18% increase in bone volume (BV/TV). These results support the role of Cn/NFAT in osteoblast formation and differentiation in vivo. To demonstrate the role of Cn/NFAT in osteoblast differentiation in vitro, MC3T3-E1 cells were cultured for 14 days and 21 days and treated with different concentrations of CsA. Cells were stained for alkaline phosphatase activity and mineralization. In addition, osteoblastic gene marker expression was also examined. Our results demonstrate that the inhibition of Cn/NFAT increases osteoblast differentiation dose dependently. Furthermore, quantitative polymerase chain reaction analyses demonstrate that the inhibition of Cn/NFAT by CsA, dose dependently, increases the expression of alkaline phosphatase and osteocalcin. Taken together, these data confirm that the inhibition of Cn/NFAT by CsA increases osteoblast differentiation and bone formation both in vivo and in vitro.
To elucidate the mechanism by which NFAT inhibition increases bone formation, we examined the expression of Fra-2, a transcription factor that is known to be associated with osteoblast differentiation. Here we show that CsA increases Fra-2 gene and protein expression as well as AP-1 DNA binding activity. Furthermore, the direct inhibition of NFATc1 by siRNA increases Fra-2 protein expression in osteoblasts.
CONCLUSION
We demonstrate that NFATc1 negatively regulates osteoblast differentiation by regulating Fra-2 expression. Findings from our study will provide the first documentation of a novel molecular mechanism that describes the role of NFATc1 in osteoblast differentiation. A basis will thereby be provided for the development of a new target for drug design and therapeutic intervention to combat osteoporosis.
